表紙
市場調査レポート

男性疾患治療市場(〜2017年):2012年から市場成長を抑制する、ジェネリック医薬品シルデナフィル(sildenafil)の可用性

Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth

発行 GBI Research 商品コード 228476
出版日 ページ情報 英文 130 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
男性疾患治療市場(〜2017年):2012年から市場成長を抑制する、ジェネリック医薬品シルデナフィル(sildenafil)の可用性 Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
出版日: 2012年01月16日 ページ情報: 英文 130 Pages
概要

当レポートでは、男性特有の疾患と治療市場について調査分析し、市場に影響を与える促進要因と障壁について検証し、主要地域/適応別に、治療の利用形態、市場の収益、年間治療費(ACT)の予測(〜2017年)を提供して、主要企業プロファイルも含め、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場の特徴

  • 概要
  • 市場予測
  • 世界のジェネリック/オフラベル(適応外)医薬品のシェア
  • 年間治療費
  • 治療の利用形態

第4章 地域情勢

  • 市場予測:国別
  • 米国
  • 欧州主要5ヶ国
  • 日本
    • 市場予測
    • 年間治療費
    • 治療の利用形態

第5章 治療情勢

  • 世界の勃起不全(ED)治療市場
  • 世界の男性性腺機能低下症治療市場
  • 世界の早漏(PE)治療市場
  • 世界の良性前立腺過形成(BPH)治療市場
    • 市場概要
    • 市場予測
    • 収益分析:国別
    • ジェネリック/オフラベル(適応外)医薬品のシェア
    • 年間治療費
    • 治療アルゴリズム
    • 治療の利用形態
    • 製品分析
    • 市場促進要因と抑制要因

第6章 パイプライン分析

  • 概要
  • 研究開発パイプライン:適応別
  • 研究開発パイプライン:開発段階別
  • 研究開発パイプライン:勃起不全(ED)
  • 研究開発パイプライン:早漏
  • 研究開発パイプライン:男性性腺機能低下症
  • 研究開発パイプライン:良性前立腺過形成(BPH)

第7章 競合情勢

  • 概要
  • 企業プロファイル
    • Pfizer Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline, Inc
    • Abbott Laboratories
    • Endo Pharmaceuticals Holding Inc.
    • Bayer Healthcare AG
    • Johnson & Johnson
    • VIVUS, Inc.
    • Auxilium Pharmaceuticals, Inc.

第8章 戦略的統合

  • 概要
  • M&A
  • ライセンス契約
  • 主なライセンス契約
  • 共同開発案件

第9章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Summary

GBI Research finds that the men's health therapeutics market will continue to grow only moderately. The principal reason for this stagnancy will be the first patent expiry of a top selling blockbuster, Viagra. The overall men's health market is driven by the launch of late-stage pipeline candidates and the steady increase in the diseased and treated population. The erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) markets constitute a major portion of the men's health market. In 2010, these markets accounted for more than 80% of the total men's health therapeutics market. Male hypogonadism accounted for 8.6% of the total market size. The premature ejaculation market represents a small portion of the total men's health market. The premature ejaculation market does not have any FDA approved products in the major market geographies. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of promising new drugs in the future. In 2009, the global men's health therapeutics market was estimated to be worth $9,162m. GBI Research forecasts the market to grow at a compound annual growth rate (CAGR) of approximately 4.1% between 2010 and 2017 to record a sales value of approximately $12,163m by 2017.

The men's health market has a moderate level of unmet needs. The current treatment options in the erectile dysfunction and male hypogonadism market are efficacious and have a manageable safety profile with the exception of some rare but serious side effects. The unmet need in the premature ejaculation market is huge. This is because the market lacks any FDA approved products for treatment of the disease in major geographies. There exists an opportunity for pharmaceutical companies to produce drugs with improved efficacy, improved patient compliance and competitive pricing in the future. The men's health pipeline does contain few potential drugs which will help sustain market growth in the forecast period. However, the men's health Research and Development (R&D) pipeline is not very innovative, with most of the projects in the late stage pipeline being me-too products.

Scope

  • Annualized market data for the men's health therapeutics market from 2002 to 2010 and forecast to 2017.
  • Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism, premature ejaculation and benign prostatic hyperplasia.
  • Analysis of the men's health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the men's health therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annual cost of treatment, a treatment flow algorithm and treatment usage patterns.
  • Key drivers and restraints that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Bayer Healthcare AG, Abbott Laboratories, Endo Pharmaceuticals Holding Inc., Johnson and Johnson, VIVUS Inc. and Auxilium Pharmaceuticals, Inc.
  • Key M&A activities and licensing agreements, that have taken place in the period 2004-2011 in the global men's health therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with the highest growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research “Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth”. The report provides in-depth analysis on the drivers and barriers that affect the global men's health therapeutics market. The report analyzes the markets for men's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, market revenue, and the annual cost of treatment (ACT) are forecast until 2017 for the key geographies, as well as for the leading therapeutic segments. Furthermore, the report provides profiles of the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research indicates that the global men's health therapeutics market has been one of the fastest growing markets in the pharmaceutical industry. However, the market growth is expected to slow down in the future due to various restraints such as the expiry of the patents of key drugs, and a low treatment seeking and diagnosis rate. Nevertheless, the global men's health therapeutics market is still forecast to grow at a moderate rate in the future.

The Global Men's Health Market is Forecast to Show Moderate Growth during the Forecast Period

In 2010, the global men's health market was estimated to be worth $9,162m, representing a Compound Annual Growth Rate (CAGR) of 8.4% between 2002 and 2010. By 2017, the global men's health market is estimated to reach $12,163m, indicating a CAGR of 4.1% between 2010 and 2017. The major reason for the reduced growth rate is the first patent expiry of the blockbuster drug, Viagra (sildenafil citrate) in 2012. The drug contributes significantly to the entire men's health market, and accounts for more than 55% of the market's revenue. As a result, the patent expiry of this drug will directly affect the market's growth.

The men's health pipeline portfolio comprises both me-too and first-in-class molecules in the late stage of development. These molecules are expected to be launched during the forecast period. Some of these pipeline candidates offer improved therapeutic outcomes and a better safety profile compared to current market products. If launched, these drugs will offer physicians and patients better treatment options. This will boost the market growth.

In addition, a steady increase in the diseased population and in the treated population will sustain modest market growth during the forecast period.

Men's Health Pipeline Portfolio is Dominated by Late-stage Pipeline Candidates

The men's health pipeline portfolio has 64 molecules across different developmental stages. The number of pipeline candidates in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 68% of the total number of pipeline molecules. In addition, the pipelines of two major markets, erectile dysfunction (ED) and Benign Prostatic Hyperplasia (BPH) constitute approximately 69% of the total men's health pipeline. This indicates that the launch of the key late stage pipeline molecules will boost the ED and BPH markets in particular.

The ED pipeline consists of me-too molecules in Phase III such as alfuzosin and Zydena (udenafi). These drugs are phosphodiesterase type 5 inhibitors and expected to be launched in the near future. Moreover, New Drug Application (NDA) filed molecules such as avanafil and Vitaros (alprostadil) are first-in-class molecules. The launch of these molecules will support the market growth.

The male hypogonadism market has two molecules in the regulatory filing stage. These molecules offer some benefits over the current market products. The BPH market consists of eight molecules in Phase III and one molecule in the regulatory filing stage. The launch of these molecules will sustain the market growth during the forecast period. The PE market does not have any current FDA approved products in major geographies. The market is primarily dominated by off-label drugs. However the introduction of late stage pipeline drugs in the market will significantly boost the market growth.

Major Strategic Consolidations have Driven the Men's Health Market

Between 2004 and 2010, the men's health therapeutic sector witnessed numerous strategic consolidations. With about 93 strategic consolidations, the men's health therapeutics sector was on a significant growth path during 2004-2010. There have been increasing numbers of licensing agreements for drugs in the approval stages. Geographically, the emerging nations are seen as regions with strong market opportunity and therefore the number of licensing agreements in these nations is expected to increase. Major licensing agreements in 2010 included Eli Lilly's licensing agreement with Acrux for the commercialization of Axiron (testosterone topical solution); a merger agreement between Biovail Corp. and Valeant Pharmaceuticals; and the acquisition of ICOS by Eli Lilly in 2007 collectively accounted for approximately $6,995m in terms of deal value. These have strengthened the financial stability of the men's health market players.

Most of the licensing agreements were focused on co-promotion, distribution, adding a new product to their existing portfolio, marketing, and receiving full marketing rights for the original product. The US accounted for more than 50% of strategic consolidation activities. Analysis suggests that most of the pharmaceutical companies find it beneficial to license a drug in the approval stage.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Men's Health Therapeutics Market to 2017 - Introduction

  • 2.1. Overview
  • 2.2. GBI Research Report Guidance

3. Men's Health Therapeutics Market to 2017 - Market Characterization

  • 3.1. Overview
  • 3.2. Market Forecasts
  • 3.3. Global Generic/Off-label Share
  • 3.4. Annual Cost of Treatment
  • 3.5. Treatment Usage Patterns
    • 3.5.1. Diseased Population
    • 3.5.2. Treatment Seeking Population
    • 3.5.3. Diagnosed Population
    • 3.5.4. Treated Population
    • 3.5.5. Drivers and Restraints of the Men's Health Therapeutics Market

4. Men's Health Therapeutics Market To 2017 - Geographical Landscape

  • 4.1. Market Forecasts by Country
  • 4.2. The US
    • 4.2.1. Market Forecasts
    • 4.2.2. Annual Cost of Treatment
    • 4.2.3. Treatment Usage Patterns
  • 4.3. Top Five Countries in Europe
    • 4.3.1. Market Forecasts
    • 4.3.2. Annual Cost of Treatment
    • 4.3.3. Treatment Usage Patterns
  • 4.4. Japan
    • 4.4.1. Market Forecasts
    • 4.4.2. Annual Cost of Treatment
    • 4.4.3. Treatment Usage Patterns

5. Men's Health Therapeutics Market to 2017 - Therapeutic Landscape

  • 5.1. Global Erectile Dysfunction (ED) Therapeutics Market
    • 5.1.1. Market Overview
    • 5.1.2. Market Forecasts
    • 5.1.3. Revenue Analysis by Country
    • 5.1.4. Global Generic/Off-Label Share
    • 5.1.5. Annual Cost of Treatment
    • 5.1.6. Treatment Flow Algorithm
    • 5.1.7. Treatment Usage Patterns
    • 5.1.8. Product Analysis
    • 5.1.9. Drivers and Restraints of the ED Therapeutics Market
  • 5.2. Global Male Hypogonadism Therapeutics Market
    • 5.2.1. Market Overview
    • 5.2.2. Market Forecasts
    • 5.2.3. Revenue Analysis by Country
    • 5.2.4. Global Generic/Off-label Share
    • 5.2.5. Annual Cost of Treatment
    • 5.2.6. Treatment Flow Algorithm
    • 5.2.7. Treatment Usage Patterns
    • 5.2.8. Product Analysis
    • 5.2.9. Drivers and Restraints of the Male Hypogonadism Therapeutics Market
  • 5.3. Global Premature Ejaculation (PE) Therapeutics Market
    • 5.3.1. Market Overview
    • 5.3.2. Market Forecasts
    • 5.3.3. Revenue by Country
    • 5.3.4. Global Generic/Off-Label Share
    • 5.3.5. Annual Cost of Treatment
    • 5.3.6. Treatment Flow Algorithm
    • 5.3.7. Treatment Usage Patterns
    • 5.3.8. Product Analysis
    • 5.3.9. Drivers and Restraints of the PE Therapeutics Market
  • 5.4. Global Benign Prostatic Hyperplasia (BPH) Market
    • 5.4.1. Overview
    • 5.4.2. Market Forecasts
    • 5.4.3. Revenue Analysis by Country
    • 5.4.4. Generics/Off-Label Share
    • 5.4.5. Annual Cost of Treatment
    • 5.4.6. Treatment Flow Algorithm
    • 5.4.7. Treatment Usage Patterns
    • 5.4.8. Product Analysis
    • 5.4.9. Drivers and Restraints of the BPH Therapeutics Market

6. Men's Health Therapeutics Market to 2017 - Pipeline Analysis

  • 6.1. Overview
  • 6.2. Research and Development Pipeline by Indication
  • 6.3. Research and Development by Phase of Development
  • 6.4. Research and Development Pipeline - Erectile Dysfunction
    • 6.4.1. Pipeline by Clinical Phases of Development
    • 6.4.2. Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market
  • 6.5. Research and Development Pipeline - Premature Ejaculation
    • 6.5.1. Pipeline by Clinical Phases of Development
    • 6.5.2. Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market
  • 6.6. Research and Development Pipeline - Male Hypogonadism
    • 6.6.1. Pipeline by Clinical Phases of Development
    • 6.6.2. Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market
  • 6.7. Research and Development Pipeline - Benign Prostatic Hyperplasia
    • 6.7.1. Pipeline by Clinical Phases of Development
    • 6.7.2. Profiles of Key Late-Stage Drugs in the Benign Prostatic Hyperplasia Market

7. Men's Health Therapeutics Market to 2017 - Competitive Landscape

  • 7.1. Overview
  • 7.2. Company Profiles
    • 7.2.1. Pfizer Inc.
    • 7.2.2. Eli Lilly and Company
    • 7.2.3. GlaxoSmithKline, Inc
    • 7.2.4. Abbott Laboratories
    • 7.2.5. Endo Pharmaceuticals Holding Inc.
    • 7.2.6. Bayer Healthcare AG
    • 7.2.7. Johnson & Johnson
    • 7.2.8. VIVUS, Inc.
    • 7.2.9. Auxilium Pharmaceuticals, Inc.

8. Men's Health Therapeutics Market to 2017 - Strategic Consolidations

  • 8.1. Overview
  • 8.2. Mergers and Acquisitions
    • 8.2.1. Overview
    • 8.2.2. Major M&A Deals
  • 8.3. Licensing Agreements
    • 8.3.1. Deals by Geography
    • 8.3.2. Deals by Value
    • 8.3.3. Deals by Year
  • 8.4. Major Licensing Agreements
  • 8.5. Co-Development Deals
    • 8.5.1. Major Co-Development Deals

9. Men's Health Therapeutics Market to 2017 - Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
    • 9.3.3. Primary Research
    • 9.3.4. Therapeutic Landscape
    • 9.3.5. Epidemiology-based Forecasting
    • 9.3.6. Market Size by Geography
    • 9.3.7. Geographical Landscape
    • 9.3.8. Pipeline Analysis
    • 9.3.9. Competitive Landscape
    • 9.3.10. Expert Panel Validation
  • 9.4. Contact Us
  • 9.5. Disclaimer
  • 9.6. Sources

List of Tables

  • Table 1: Men's Health Therapeutics Market to 2017, Global, Revenue, $m, 2002-2010
  • Table 2: Men's Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2010-2017
  • Table 3: Men's Health Therapeutics Market to 2017, Global, Annual Cost of Treatment, $, 2002-2010
  • Table 4: Men's Health Therapeutics Market to 2017, Global, Annual Cost of Treatment ,$, 2010-2017
  • Table 5: Men's Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2002-2010
  • Table 6: Men's Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2010-2017
  • Table 7: Men's Health Therapeutics Market to 2017, Global, Revenue Analysis by Country, $m, 2002-2010
  • Table 8: Men's Health Therapeutics Market to 2017, Global, Revenue Analysis by Country, $m, 2010-2017
  • Table 9: Men's Health Therapeutics Market to 2017, The US, Revenue, $m, 2002-2010
  • Table 10: Men's Health Therapeutics Market to 2017, The US, Revenue Forecasts ,$m, 2010-2017
  • Table 11: Men's Health Therapeutics Market to 2017, The US, Annual Cost of Treatment, $, 2002-2010
  • Table 12: Men's Health Therapeutics Market to 2017, The US, Annual Cost of Treatment, $, 2010-2017
  • Table 13: Men's Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2002-2010
  • Table 14: Men's Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2010-2017
  • Table 15: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue, $m, 2002-2010
  • Table 16: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Forecasts, $m, 2010-2017
  • Table 17: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2002-2010
  • Table 18: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2010-2017
  • Table 19: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2002-2010
  • Table 20: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2010-2017
  • Table 21: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2002-2010
  • Table 22: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2010-2017
  • Table 23: Men's Health Therapeutics Market to 2017, Japan, Revenue, $m, 2002-2010
  • Table 24: Men's Health Therapeutics Market to 2017, Japan, Revenue Forecasts, $m, 2010-2017
  • Table 25: Men's Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2002-2010
  • Table 26: Men's Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2010-2017
  • Table 27: Men's Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2002-2010
  • Table 28: Men's Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2010-2017
  • Table 29: Erectile Dysfunction Therapeutics Market, Global, Revenue, $m, 2002-2010
  • Table 30: Erectile Dysfunction Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
  • Table 31: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010
  • Table 32: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017
  • Table 33: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010
  • Table 34: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
  • Table 35: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2010
  • Table 36: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2010-2017
  • Table 37: Male Hypogonadism Therapeutics Market, Global, Revenue, $m, 2002-2010
  • Table 38: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
  • Table 39: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010
  • Table 40: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017
  • Table 41: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010
  • Table 42: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
  • Table 43: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2010
  • Table 44: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2010-2017
  • Table 45: Premature Ejaculation Therapeutics Market, Global, Revenue, $m, 2002-2010
  • Table 46: Premature Ejaculation Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
  • Table 47: Premature Ejaculation Therapeutics Market, Global, Revenue by Country ,$m, 2002-2010
  • Table 48: Premature Ejaculation Therapeutics Market, Global, Revenue by Country, $m, 2010-2017
  • Table 49: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment , $, 2002-2010
  • Table 50: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
  • Table 51: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2010
  • Table 52: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, million, 2010-2017
  • Table 53: BPH Therapeutics Market, Global, Revenue, $bn, 2002-2010
  • Table 54: BPH Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017
  • Table 55: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010
  • Table 56: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017
  • Table 57: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010
  • Table 58: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
  • Table 59: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010
  • Table 60: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017
  • Table 61: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Indication, (%), 2011
  • Table 62: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase, (%), 2011
  • Table 63: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Erectile Dysfunction Market, (%), 2011
  • Table 64: Erectile Dysfunction Therapeutics Market, Global, Discovery Pipeline Molecules, 2011
  • Table 65: Erectile Dysfunction Therapeutics Market, Global, Preclinical/IND Filed Pipeline Molecules, 2011
  • Table 66: Erectile Dysfunction Therapeutics Market, Global, Phase I Pipeline Molecules, 2011
  • Table 67: Erectile Dysfunction Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
  • Table 68: Erectile Dysfunction Therapeutics Market, Global, Phase III Pipeline Molecules, 2011
  • Table 69: Erectile Dysfunction Therapeutics Market, Global, NDA Filed Molecules, 2011
  • Table 70: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in the Premature Ejaculation Market, (%), 2011
  • Table 71: Premature Ejaculation Therapeutics Market. Global, Discovery Pipeline Molecules, 2011
  • Table 72: Premature Ejaculation Therapeutics Market. Global, Preclinical Pipeline Molecules, 2011
  • Table 73: Premature Ejaculation Therapeutics Market. Global, Phase I Pipeline Molecules, 2011
  • Table 74: Premature Ejaculation Therapeutics Market. Global, Phase II Pipeline Molecules, 2011
  • Table 75: Premature Ejaculation Therapeutics Market. Global, Phase III Pipeline Molecules, 2011
  • Table 76: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Male Hypogonadism, (%), 2011
  • Table 77: Male Hypogonadism Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011
  • Table 78: Male Hypogonadism Therapeutics Market, Global, Phase I Pipeline Molecules, 2011
  • Table 79: Male Hypogonadism Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
  • Table 80: Male Hypogonadism Therapeutics Market, Global, NDA Filed Pipeline Molecules, 2011
  • Table 81: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Benign Prostatic Hyperplasia, (%), 2011
  • Table 82: Benign Prostatic Hyperplasia Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011
  • Table 83: Benign Prostatic Hyperplasia Market, Global, Phase I Pipeline Molecules, 2011
  • Table 84: Benign Prostatic Hyperplasia Market, Global, Phase II Pipeline Molecules, 2011
  • Table 85: Benign Prostatic Hyperplasia Market, Global, Phase III Pipeline Molecules, 2011
  • Table 86: Benign Prostatic Hyperplasia Market, Global, NDA Filed Pipeline Molecules, 2011
  • Table 87: Men's Health Therapeutics Market to 2017, Eli Lilly and Company, Men's Health Pipeline, 2010
  • Table 88: Men's Health Therapeutics Market to 2017, GlaxoSmithKline, Inc., Men's Health Pipeline, 2010
  • Table 89: Men's Health Therapeutics Market to 2017, Abbott Laboratories, Men's Health Pipeline, 2010
  • Table 90: Men's Health Therapeutics Market to 2017, Endo Pharmaceuticals Holding Inc, Men's Health Pipeline, 2010
  • Table 91: Men's Health Therapeutics Market to 2017, Bayer Healthcare AG, Men's Health Pipeline, 2010
  • Table 92: Men's Health Therapeutics Market to 2017, VIVUS Inc., Men's Health Pipeline, 2010
  • Table 93: Men's Health Therapeutics Market to 2017, Global, Deals by Type, 2004-2011
  • Table 94: Men's Health Therapeutics Market to 2017, Global, M&A Deals by Value, (%), 2004-2011
  • Table 95: Men's Health Therapeutics Market to 2017, Global, M&A Deals by Geography, (%), 2004- 2011
  • Table 96: Men's Health Therapeutics Market to 2017, Global, Number of M&A Deals by Year, 2004-2011
  • Table 97: Men's Health Therapeutics Market to 2017, Global, Major M&A Deals, 2007-2011
  • Table 98: Men's Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Geography (%), 2004-2011
  • Table 99: Men's Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Value, ($m), (%), 2004-2011
  • Table 100: Men's Health Therapeutics Market to 2017, Global, Number of Licensing Deals by Year, 2004-2011
  • Table 101: Men' Health Therapeutics Market to 2017, Major Licensing Agreements, 2009-2010
  • Table 102: Men's Health Therapeutics Market to 2017, Global, Major Co-Development Deals, 2004-2006

List of Figures

  • Figure 1: Men's Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2002-2017
  • Figure 2: Men's Health Therapeutics Market to 2017, Global, Generic/Off-label Share, %, 2010, 2017
  • Figure 3: Men's Health Therapeutics Market to 2017, Global, Annual Cost of Treatment, $, 2002-2017
  • Figure 4: Men's Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2002-2017
  • Figure 5: Men's Health Therapeutics Market to 2017, Global, Diseased Population, million, 2002-2017
  • Figure 6: Men's Health Therapeutics Market to 2017, Global, Treatment Seeking Population, million, 2002-2017
  • Figure 7: Men's Health Therapeutics Market to 2017, Global, Diagnosed Population, million, 2002-2017
  • Figure 8: Men's Health Therapeutics Market to 2017, Global, Treated Population, million, 2002-2017
  • Figure 9: Men's Health Therapeutics Market to 2017, Global, Market Drivers and Restraints
  • Figure 10: Men's Health Market to 2017, Revenue Analysis by Country, $m, 2002-2017
  • Figure 11: Men's Health Therapeutics Market to 2017, The US, Revenue Forecasts ,$m, 2002-2017
  • Figure 12: Men's Health Therapeutics Market to 2017, The US, Annual Cost of Treatment ,$, 2002-2017
  • Figure 13: Men's Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2002-2017
  • Figure 14: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Forecasts, $m, 2002-2017
  • Figure 15: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2002-2017
  • Figure 16: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2002-2017
  • Figure 17: Men's Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2002-2017
  • Figure 18: Men's Health Therapeutics Market to 2017, Japan, Revenue Forecasts, $m, 2002-2017
  • Figure 19: Men's Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2002-2017
  • Figure 20: Men's Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2002-2017
  • Figure 21: Erectile Dysfunction Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
  • Figure 22: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017
  • Figure 23: Erectile Dysfunction Therapeutics Market, Global Generic/Off-Label Share, (%), 2010, 2017
  • Figure 24: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
  • Figure 25: Erectile Dysfunction Therapeutics Market, Global, Treatment Flow Algorithm for Erectile Dysfunction, 2011
  • Figure 26: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2017
  • Figure 27: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
  • Figure 28: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017
  • Figure 29: Male Hypogonadism Therapeutics Market, Global, Global Generic/Off-Label Share, $m, 2010, 2017
  • Figure 30: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
  • Figure 31: Male Hypogonadism Therapeutics Market, Global, Treatment Flow Algorithm for Male Hypogonadism, 2011
  • Figure 32: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2017
  • Figure 33: Male Hypogonadism Therapeutics Market to 2017, Global, Prescription Share Analysis, (%), 2010
  • Figure 34: Premature Ejaculation Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
  • Figure 35: Premature Ejaculation Therapeutics Market, Global, Revenue by Country, $m, 2002-2017
  • Figure 36: Premature Ejaculation Therapeutics Market, Global Generic Share, $m, 2010- 2017
  • Figure 37: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
  • Figure 38: Premature Ejaculation Therapeutics Market, Global, Treatment Flow Algorithm for Premature Ejaculation
  • Figure 39: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002-2017
  • Figure 40: BPH Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 41: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017
  • Figure 42: BPH Therapeutics Market, Global Generics/Off-Label Share, %, 2010, 2017
  • Figure 43: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
  • Figure 44: BPH Therapeutics Market, Global, Treatment Flow Algorithm for BPH, 2011
  • Figure 45: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017
  • Figure 46: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Indication, (%), 2011
  • Figure 47: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase, (%), 2011
  • Figure 48: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Erectile Dysfunction Market, (%), 2011
  • Figure 49: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in the Premature Ejaculation Market, (%), 2011
  • Figure 50: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Male Hypogonadism, (%), 2011
  • Figure 51: Men's Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Benign Prostatic Hyperplasia, (%), 2011
  • Figure 52: Men's Health Therapeutics Market to 2017, Pfizer Inc., SWOT Analysis, 2011
  • Figure 53: Men's Health Therapeutics Market to 2017, Eli Lilly and Company, SWOT Analysis, 2010
  • Figure 54: Men's Health Therapeutics Market to 2017, GlaxoSmithKline, Inc, SWOT Analysis, 2010
  • Figure 55: Men's Health Therapeutics Market to 2017, Abbott Laboratories, SWOT Analysis, 2010
  • Figure 56: Men's Health Therapeutics Market to 2017, Endo Pharmaceuticals Holding Inc, SWOT Analysis, 2010
  • Figure 57: Men's Health Therapeutics Market to 2017, Bayer Healthcare AG, SWOT Analysis, 2010
  • Figure 58: Men's Health Therapeutics Market to 2017, Johnson & Johnson, SWOT Analysis, 2010
  • Figure 59: Men's Health Therapeutics Market to 2017, VIVUS Inc., SWOT Analysis, 2010
  • Figure 60: Men's Health Therapeutics Market to 2017, Auxilium Pharmaceuticals, Inc, SWOT Analysis, 2010
  • Figure 61: Men's Health Therapeutics Market to 2017, Global, Deals by Type, (%), 2004-2011
  • Figure 62: Men's Health Therapeutics Market to 2017, Global, M&A Deals by Value, (%), 2004-2011
  • Figure 63: Men's Health Therapeutics Market to 2017, Global, M&A Deals by Geography, (%), 2004- 2011
  • Figure 64: Men's Health Therapeutics Market to 2017, Global, Number of M&A Deals by Year, 2004-2011
  • Figure 65: Men's Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Geography, (%), 2004-2011
  • Figure 66: Men's Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Value, $m, (%), 2004-2011
  • Figure 67: Men's Health Therapeutics Market to 2017, Global, Number of Licensing Deals by Year, 2004-2011
  • Figure 68: GBI Research Market Forecasting Model
Back to Top